With an objective of not giving any such scope for price escalation as Martin Shkreli did for Daraprim generic drug, US Food and Drug Administration (US FDA) has turned very cautious on approvals to generic drugs. US FDA is now reviewing new applications for generic drugs, while ensuring no such lapses of price escalation.
Turing Pharmaceuticals
Breaking News
Martin Shkreli is looking for new lawyers to help him fight securities fraud charges. The request has been filed by his current lawyers to the Judge Kiyo Matsumoto. The lawyers also asked to delay a status conference set for Wednesday.
Last December, Martin Shkreli, who was arrested for securities fraud in pharmaceutical company was released on bail. Court document shows his $5 million security bond was secured with $45 million E-Trade account.
Turing Pharmaceuticals said that it won't cut the list price of the drug. However, it will negotiate discount price with hospital. Last September, Turing Pharmaceuticals raised the price of live-saving drugs, Daraprim by more than fifty times.
Subscribe to VCpost newsletter
Most Popular
- Nestle Cuts Sales Forecast as Shoppers Reject Price Hikes
- Social Security Payments Worth Over $4,800 To Go Out This Week; Here’s When You’ll Get Yours
- US Could See Another ‘Great Resignation’ as 3 in 10 Workers Plan To Quit in 2024: Survey
- Uber, Lyft Drivers Remain as Contractors After California Supreme Court Upheld Proposition 22
- Maersk Agrees to Settlement with US Labor Department After Firing Whistleblower
- Walmart Eyes $200 Million Investment in Autonomous Forklifts
- Delta’s CEO Flew to Paris for the Olympics While His Company Is Under Federal Investigation: Report
- Wiers Farm Recalls Produce Products Due To Potential Listerian Contamination